<DOC>
	<DOCNO>NCT01655706</DOCNO>
	<brief_summary>This study pilot ass feasibility protocol patient control across six participate site . The goal identify biological marker ( biomarkers ) measure baseline early treatment predict treatment outcome individual patient Major Depressive Disorder ( MDD ) . Biomarkers interest clinical ( use interview self-report measure ) , molecular ( blood sample ) neurobiological ( use neuroimaging EEG ) .</brief_summary>
	<brief_title>Canadian Biomarker Integration Network Depression Study</brief_title>
	<detailed_description>This study collect clinical biomarker data use build model predict treatment response . This study evaluate efficacy medication , medication study approve Health Canada widely use treatment MDD . This open label study involve MDD patient healthy controls.Patients diagnosis MDD current major depressive episode ( MDE ) receive open-label standard care treatment escitalopram ( 10-20mg ) . Healthy control receive medication ; however , go clinical assessment , blood collection neuroimaging procedure . At week 8 , patient assess medication response ( response define ≥ 50 % reduction MADRS score baseline ) . Responders continue medication effective dose study endpoint non-responders receive open label add-on treatment aripiprazole ( 2-10mg ) . There approximately 7 clinic visit 16 week period patient healthy control undergo clinician administer scale self report , provide blood urine sample ( undergo proteomic genomic analysis ) well neuroimaging ( fMRI EEG ) . At end study , mathematical modeling method use integrate data various modality see feature best predict treatment outcome .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>For Depressed patient : Outpatients 1860 year age Meet DSMIVTR criterion Major Depressive Episode Major Depressive Disorder MINI Episode duration ≥ 3 month Free psychotropic medication least 5 halflives ( i.e . 1 week antidepressant , 5 week fluoxetine ) baseline Visit 1 MADRS ≥ 24 Fluency English , sufficient complete interview selfreport questionnaires Any Axis I diagnosis MDD consider primary diagnosis Bipolar I Bipolar II diagnosis Presence significant Axis II diagnosis ( borderline , antisocial ) High suicidal risk , define clinician judgment Substance dependence/abuse past 6 month Presence significant neurological disorder , head trauma unstable medical condition Pregnant breastfeeding Failure 3 adequate pharmacologic intervention ( determine Antidepressant Treatment History Form ) Started psychological treatment within past 3 month intent continue treatment Patients previously fail escitalopram show intolerance escitalopram patient risk hypomanic switch ( i.e . history antidepressant hypomania ) Inclusion criterion Healthy Controls : 18 60 year age No history Axis I Axis II disorder , determine MINI . Fluency English , sufficient complete interview selfreport questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>major depression</keyword>
	<keyword>major depressive disorder</keyword>
	<keyword>biomarkers</keyword>
	<keyword>escitalopram</keyword>
	<keyword>aripiprazole</keyword>
	<keyword>MDD</keyword>
	<keyword>neuroimaging</keyword>
	<keyword>proteomic</keyword>
	<keyword>genomics</keyword>
</DOC>